Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
EMEA recommends the approval of thalidomide for the treatment of multiple myeloma (rare bone-marrow cancer)
Notice type:
Advisory
Date:
24/01/2008
Product name or type:
Thalidomide Pharmion
Active Substance:
Thalidomide
Problem Or Issue:
The European Medicines Agency (EMEA) has recommended approval of Thalidomide Pharmion across the EU for the treatment of multiple myeloma, a rare form of bone marrow cancer. Subject to granting of the market authorization by the European Commission, treatment with Thalidomide Pharmion should only be initiated and monitored by doctors with experience in the treatment of multiple myeloma. A risk management plan that includes actions to prevent pregnancy in women treated with thalidomide and exposure of their unborn children has been approved. Educational materials for healthcare professionals and patients will be provided about the treatment related risks and the precautions required to ensure safe use of the product.
Background Information Or Related Documents:
EMEA recommends the approval of thalidomide for the treatment of multiple myeloma (rare bone-marrow cancer) Document
Further Information:
For further information,
Please click here:
Press Release
« Back
Date Printed: 26/04/2024